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Cr2-/- mice reduces the extent of secondary brain
damage after closed head injury
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Jenée Patane1, Michael A Flierl1, Liudmila Kulik2, V Michael Holers2 and Philip F Stahel1,3*Abstract
Complement activation at the C3 convertase level has been associated with acute neuroinflammation and
secondary brain injury after severe head trauma. The present study was designed to test the hypothesis that
Cr2-/- mice, which lack the receptors CR2/CD21 and CR1/CD35 for complement C3-derived activation fragments,
are protected from adverse sequelae of experimental closed head injury. Adult wild-type mice and Cr2-/- mice
on a C57BL/6 genetic background were subjected to focal closed head injury using a standardized weight-drop
device. Head-injured Cr2-/- mice showed significantly improved neurological outcomes for up to 72 hours after
trauma and a significantly decreased post-injury mortality when compared to wild-type mice. In addition, the
Cr2-/- genotype was associated with a decreased extent of neuronal cell death at seven days post-injury. Western
blot analysis revealed that complement C3 levels were reduced in the injured brain hemispheres of Cr2-/- mice,
whereas plasma C3 levels remained unchanged, compared to wild-type mice. Finally, head-injured Cr2-/- had an
attenuated extent of post-injury C3 tissue deposition, decreased astrocytosis and microglial activation, and attenuated
immunoglobulin M deposition in injured brains compared to wild-type mice. Targeting of these receptors for
complement C3 fragments (CR2/CR1) may represent a promising future approach for therapeutic immunomodulation
after traumatic brain injury.
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Traumatic brain injury (TBI) is considered an ‘immuno-
logical disease’ due to the significant posttraumatic alter-
ations in host-mediated immune functions in the central
nervous system (CNS) and in the periphery [1-3]. The
complement system has been implicated in the acute
inflammatory pathophysiology of severe brain injury by
mediating blood-brain barrier (BBB) breakdown, cerebral
edema, and delayed neuronal cell death [4-6]. Com-
plement C3 represents the central molecule of the com-
plement cascade at the point where the three main
initiation pathways (classical, alternative, and lectin) merge* Correspondence: philip.stahel@dhha.org
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unless otherwise stated.[7]. Elevated post-injury C3 levels were found in the
intracranial compartment in experimental TBI models
in rats, and in head-injured patients [8-10]. Both the
depletion of C3 and the inhibition of C3 convertases
has been shown to attenuate the extent of secondary
brain injury in experimental animal models [11-13].
Complement receptor type 1 (CR1/CD35) and type 2
(CR2/CD21) are receptors for C3-derived activation
fragments (C3b, iC3b, C3d, C3dg) [7]. Of these, CR2
has been identified as a crucial ‘link’ between innate and
adaptive immunity by bridging the complement system
to B cell-mediated humoral immune responses [14]. For
example, CR2 forms an important co-receptor on B
cells during antigen-induced activation through the B
cell receptor (BCR) and subsequent signal transduction
[7,14]. A recent focus of research has been devoted to
the role of CR2 in the development and regulation of
pathogenic natural antibodies that target neo-epitopestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CR2 have been shown to be protected from the develop-
ment of ischemia/reperfusion injury under a variety of
experimental conditions [15,16]. In the mouse, the Cr2
gene encodes both CR2 and CR1 receptors by alternative
splicing [17]. The phenotype of genetically engineered
Cr2-/- mice deficient in CR2/CR1 is characterized by
multiple immunological alterations, including an altered
natural antibody repertoire and impaired B cell responses
to antigen exposure [15,18]. In light of the important
implications of the Cr2 gene for innate and humoral
immune responses, we hypothesized that Cr2-/- mice are
protected from secondary brain damage and adverse
neurological outcome in a standardized model of ex-
perimental closed head injury [19].
Materials and methods
Cr2-/- mice
The generation and characterization of Cr2-/- mice has
been previously described [18]. Breeding pairs for the
mice used in the present study consisted of three male
and two female homozygous Cr2-/- mice that had been
previously backcrossed to a pure C57BL/6 background.
Breeding colonies were established at Denver Health
Medical Center by crossing Cr2-/- mice to wild-type
littermates on a genetic C57BL/6 background (Jackson
Laboratory, Bar Harbor, Maine, United States). The result-
ing heterozygous Cr2+/- mice (F1) were then bred to each
other to obtain 25% homozygous Cr2-/- mice in the next
generation (F2). Only homozygous Cr2-/- mice were used
for this study, and were identified by genotyping using
real-time polymerase chain reaction (PCR) analysis of tail
biopsies (Transnetyx, Cordova, Tennessee, United States).
A total of n = 102 Cr2-/- mice and n = 151 C57BL/6 wild-
type mice were used for the experiments in this study.
Rag1-/- mice
In order to investigate the potential indirect mechanisms
of CR2 that may be related to effects mediated by altered
levels of pathogenic natural antibodies, an additional set of
experiments was designed that used Rag1-/- mice which
lack mature B and T lymphocytes, and are therefore in-
capable of producing natural antibodies by B-1 cells [20].
The phenotype of Rag1-/- mice is characterized by small
lymphoid organs but not linked to any neuroanatomical,
neurological, or behavioral abnormalities [20]. Adult male
Rag1-/- mice (n = 90) on a C57BL/6 background (Jackson
Laboratory, Maine, United States) were used to investigate
the role of reconstitution of selected pathogenic natural
antibodies in our model of closed head injury.
Closed-head injury model
All mice used in this study were exclusively of male gender
(to avoid a bias regarding gender-related susceptibility tobrain injury), between 10 and 12 weeks of age, weighing
25 to 35 g, and housed in single cages for at least 7 days
before being subjected to experimental procedures. Mice
were kept in a selective pathogen-free (SPF) environment
under standardized conditions of temperature (21°C),
humidity (60%), light and dark cycles (12 h:12 h), with
food and water provided ad libitum. The study was
performed in compliance with the National Institutes of
Health (NIH) guidelines for the care and use of laboratory
animals and was approved by the Institutional Animal
Care and Use Committee of the University of Colorado
(IACUC, protocol number B-79612(01)1E). A standard-
ized weight-drop device was used for induction of focal
closed head injury to the left brain hemisphere, as previ-
ously described [19]. In brief, after induction of isoflurane
anaesthesia the skull was exposed by a longitudinal mid-
line scalp incision. The head was fixed and a 333 g weight
was dropped on the skull from a height of 2.5 cm, indu-
cing a focal blunt injury to the left hemisphere. After
trauma, all mice received supportive oxygenation with
100% O2 until fully awake. Analgesia was provided by an
intraperitoneal injection of 0.05 mg/kg fentanyl immedi-
ately prior to the experimental procedure, followed by an
injection of 0.01 mg/kg fentanyl every 12 hours until sacri-
ficed. Sham-operated mice underwent identical proce-
dures with regard to analgesia, anaesthesia, and surgical
scalp incision, but were not subjected to experimental
head trauma. For each set of experiments, four to five
mice were used per time-point and condition. Cumulative
numbers of mice per group were used for determining
neurological outcomes for up to seven days after trauma.
Neurological severity score (NSS)
The NSS represents a standardized scoring system for
the quantification of post-injury neurological outcome,
as described in detail elsewhere [19]. The score com-
prises 10 individual parameters including tasks on
motor function, alertness, and physiological behavior.
One point is awarded for the absence of a tested reflex
or for the inability to perform a specific task, and no
point for succeeding.
A maximum NSS of 10 points indicates severe neuro-
logical dysfunction with failure of all tasks, whereas a low
NSS of 0 to 2 points is characteristic of healthy uninjured
mice [19]. In this study, the NSS was assessed at the time-
points 1, 4, 12, 24, 48, and 72 hours, and 7 days after
trauma or sham surgery by two investigators who were
blinded to the study groups. The cumulative numbers of
animals included in the NSS scoring (N = 230) and stratifi-
cation by experimental groups is explained in Figure 1.
Harvest of blood samples and brain tissue
Animals were sacrificed by decapitation under isoflurane
anaesthesia at t = 4 hours, 24 hours, and 7 days after
Figure 1 Schematic depiction of cumulative numbers of mice (overall N = 230) that underwent neurological scoring, stratified by
experimental groups. d, days; TBI, traumatic brain injury; WT, wild-type.
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tracardiac puncture immediately prior to decapitation.
For collection of serum samples, whole blood was trans-
ferred to sterile serum microtubes (Sarstedt, Nümbrecht,
Germany), centrifuged at 10,000 g for 10 minutes (4°C)
and the supernatants were frozen at -80°C until analysis.
For collection of plasma samples, whole blood was
collected in sterile microtubes containing 3.5% ethyl-
enediaminetetraacetic acid (EDTA) and a protease in-
hibitor cocktail (Sigma-Aldrich, St Louis, Missouri, United
States). Samples were centrifuged at 2,000 g for 15 minutes
(4°C) and the obtained plasma stored at -80°C until analysis.
Brain samples were surgically removed after decapitation,
snap-frozen in liquid nitrogen and stored at -80°C. Prior
to analysis, brains were split into left (injured) and right
(uninjured internal control) hemispheres, and the cere-
bellum was removed. For assessment of inflammatory
and apoptotic mediators by western blots, brain hemi-
spheres were homogenized with a Tissue Master-125
Homogenizer (Omni International, Kennesaw, Georgia,
United States), as described in detail below.
TUNEL histochemistry and NeuN double-immunostaining
A standard terminal deoxynucleotidyl transferase 2'-
deoxyuridine-5'-triphosphate (dUTP) nick-end labeling
(TUNEL) staining technique was used to determine the
extent of neuronal cell death, using the In Situ Cell Death
Detection Kit, TMR red (Roche Diagnostics, Mannheim,
Germany). Sections were double-stained with a neuronal
marker to differentiate TUNEL positive neurons from
other cells types. In brief, frozen slides with serial coronal
brain cryosections of 10 μm thickness were air-dried for
30 minutes, followed by fixation in 10% formalin solu-
tion (Sigma-Aldrich) for 10 minutes. After washing in
phosphate-buffered saline (PBS), sections were blocked
with a 3% normal goat serum (Jackson ImmunoResearch
laboratories, West Grove, Pennsylvania, United States) for
1 hour at 4°C, followed by incubation in a mixture of pri-
mary antibody and NeuN at a dilution of 1:300 (Millipore,Billerica, Massachusetts, United States; catalogue number
MAB377) overnight at 4°C. Sections were rinsed and
incubated in a mixture of goat anti-mouse IgG-FITC
secondary antibody at a dilution of 1:1000 (Abcam,
Cambridge, Massachusetts, United States) for 2 hours at
room temperature. Slides were washed again and perme-
abilized in 3% Triton X-100 solution (Sigma-Aldrich) for
60 minutes. Slides were then incubated with the terminal
deoxynucleotidyl transferase (TdT) enzyme and tetra-
methylrhodamine (TMR)-labeled dUTP for 90 minutes
at 37°C. Negative control sections were incubated in
absence of the TdT enzyme. For positive controls, equal
brain sections were exposed to 500 U/ml DNase grade I
solution (Roche Diagnostics) for 20 minutes. Slides were
then cover-slipped with Vectashield mounting medium
containing 4’, 6’-diamino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, California, United States). All
sections were evaluated immediately after staining using
an Olympus BX41 fluorescence microscope (Olympus,
Center Valley, Pennsylvania, United States) at 525 nm for
NeuN fluorescence (green) and at 576 nm for TUNEL
TMR (red). Data were analyzed by QCapturePro7 software
(QImaging, Surrey, British Columbia, Canada). The
TUNEL-positive cells were counted in 15 randomly se-
lected cortical fields of 0.01 mm2 per section. Only cells
with a strong fluorescent signal for both red (TUNEL) and
green fluorescence (NeuN) were counted. Cell counts
were analyzed as mean values ± SD.
Western blot analysis
Protein levels of complement C3, pro-apoptotic (Fas-L,
Fas, Bax), and anti-apoptotic (Bcl-2) mediators were
assessed in brain homogenates and plasma samples by
western blotting. Separated brain hemispheres were
homogenized with a Tissue Master-125 homogenizer
(Omni International) in a radioimmunoprecipitation assay
(RIPA) lysis buffer containing 12.1 mM sodium deoxy-
cholate, 3.5 mM sodium dodecyl sulphate (SDS), 0.6 mM
phenylmethanesulfonyl fluoride (PMSF), 1 mM sodium
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tor cocktail (Sigma-Aldrich) in PBS. Homogenized sam-
ples were centrifuged at 16,000 g for 15 minutes (4°C) and
the supernatants stored at -80°C. For western blot analysis,
total protein concentrations of brain homogenates and
plasma samples were determined using a colorimetric
assay (BCA Protein Assay; Thermo Scientific, Rockford,
Illinois, United States). Equivalent amounts of 50 μg pro-
tein were then denatured in loading buffer (Laemmli sam-
ple buffer + 5% mercaptoethanol) and separated under
reducing conditions on 10% (Fas), 12.5% (C3, Fas-L and β-
Actin) or 15% (Bax and Bcl-2) sodium dodecyl sulfate
(SDS) polyacrylamide gels. Proteins were transferred to
nitrocellulose membranes using a dry electroblotting iBlot
system (Invitrogen, Carlsbad, California, United States).
Membranes were then blocked with 5% non-fat milk
(Nestle, Wilkes-Barre, Pennsylvania, United States) for
60 minutes and incubated overnight at 4°C with either
polyclonal anti-Fas (Santa Cruz Biotechnology, Santa Cruz,
California, United States; catalogue number Sc-1023), poly-
clonal anti-Fas ligand (Fas-L, Santa Cruz Biotechnology;
catalogue number Sc-6237), monoclonal anti-Bcl-2 (Santa
Cruz Biotechnology, catalogue number Sc-7382) or
monoclonal anti-Bax antibodies (Santa Cruz Biotech-
nology, catalogue number Sc-80658), each diluted at a
ratio of between 1:300 and 1:600, as appropriate. For
detection of complement C3, a monoclonal anti-C3
antibody from Santa Cruz Biotechnology (catalogue
number Sc-28294) was used for analysis of brain ho-
mogenates (diluted 1:10), and a monoclonal anti-C3
antibody clone ‘3d11’ from our own laboratory was used
for analysis of plasma samples (diluted 1:1,000). To
ascertain equal loading, membranes were incubated
with a monoclonal anti-β-actin antibody from Santa
Cruz Biotechnology (catalogue number Sc-47778),
diluted 1:1,000. After incubation with alkaline phosphatase
(AP)-conjugated secondary antibodies (Jackson Immu-
noResearch) for 60 minutes (diluted 1:5,000), AP detection
occurred in a nitro-blue tetrazolium/5-bromo-4-chloro-3'-
indolyphosphate (NBT/BCIP) stock solution (Roche Diag-
nostics). The following whole cell lysates were used as
internal positive controls: HL-60 for Fas-L; A-431 for Fas;
CTLL-2 for Bax; and mouse spleen extract for Bcl-2
(all from Santa Cruz Biotechnology). Western blot
band intensities were quantified using ImageJ software
(Bethesda, Maryland, United States).
Immunohistochemistry (IHC)
IHC was performed in serial coronal brain cryosections of
10 μm thickness using a standard biotin/avidin/peroxidase
technique with diaminobenzidine (DAB) as chromogen
(Vector Laboratories), as previously described [21,22].
The following primary antibodies and dilutions were
used: monoclonal anti-mouse C3 (1:20) for assessmentof C3 deposition in injured brain tissue (Hycult Biotech,
Plymouth Meeting, Pennsylvania, United States; cata-
logue number HM1045); monoclonal anti-mouse NeuN
(1:400) as a neuronal cell marker (Millipore; catalogue
number MAB377); monoclonal anti-mouse glial fibrillary
acidic protein (GFAP) (1:40) as a marker for astrocytes
(Santa Cruz Biotechnologies; catalogue number Sc-33673);
monoclonal anti-mouse CD11b (1:200) as a marker for
microglia (AbD Serotec, Raleigh, North Carolina, United
States; catalogue number MCA711); and polyclonal goat
anti-mouse immunoglobulin M (IgM) (μ chain, Jackson
ImmunoResearch; catalogue number 115-001-020) for
detection of IgM deposition in brain tissue (1:100). All
cryosections were counterstained with hematoxylin (Dako,
Carpinteria, California, United States), cover-slipped and
analyzed using an Olympus BX41 microscope and Altra
20 imaging software (Olympus). Positive IgM, microglia,
and astrocytes were quantified using OCapturePro7
software (QImaging, Surrey, British Columbia, Canada).
Positive IgMs were counted in five randomly selected
fields of 0.01 mm2 per section. Positive CD11b and
GFAP cells were tagged for intensity reading and clas-
sification of reactive microglia and astrocytes was
determined based on location and signal intensity per
0.0625 mm2 of two different brain sections.
ELISA
Serum samples were analyzed for mouse tumor necrosis
factor (TNF), interleukin (IL) -6, and IL-10 using com-
mercially available ELISA kits, according to the manu-
facturer’s instructions (R&D Systems, Minneapolis,
Minnesota, United States). In addition, serum levels of
neuron-specific enolase (NSE), an established marker of
neuronal cell death after head injury, were determined
by a commercially available ELISA, according to the
manufacturer’s protocol (Immuno-Biological Laboratories,
Minneapolis, Minnesota, United States). The C3-derived
complement activation product C3a was assessed in
plasma samples using a mouse anaphylatoxin C3a-specific
ELISA developed in our laboratory, as previously de-
scribed [21]. Optical density was read at 405 nm (NSE)
or 450 nm (C3a and cytokines) using an Anthos 2010
plate reader (BioTek, Winooski, Vermont, United States).
Purification and reconstitution of monoclonal natural IgM
Monoclonal IgM antibodies (mAbs) were developed by
the fusion of peritoneal, lymph node, and spleen cells
from wild-type C57BL/6 mice with the Sp2/0-Ag14 mye-
loma cell line to establish IgM-producing hybridomas, as
previously described [23,24]. Successful fusions were
confirmed by western blot analysis. All reagents used for
the purification of mAbs were purchased from Sigma-
Aldrich. Three positive hybridomas were selected for the
present study: B4 (mAbs recognizing annexin IV); C2
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(isotype-matched control mAb). Supernatants of cultured
hybridomas were affinity purified on columns coated with
agarose beads and anti-human IgM (μ chain), which has
been previously shown to be cross-reactive with mouse
IgM [23]. Bound IgM antibodies were washed in PBS con-
taining 0.02% sodium azide (pH 7.4), eluted with 0.2 M
glycine (pH 2.3), and collected in a 1.5 M TRIS buffer
(pH 8.8). Eluted antibody was concentrated by centrifugal
filtration using Centricon Plus-70 centrifugal filter units
(EMD Millipore). Final antibody concentration was mea-
sured by spectrophotometry at an excitation wave length
of 280 nm. Antibody purity and specificity was confirmed
by 10% SDS-gel electrophoresis. The concentrates con-
taining mAbs B4 and C2 and the isotype control (mAb
F632) were individually dissolved in sodium azide-free
PBS and stored under sterile conditions at 4°C. Natural
IgM (mAb B4 and mAb C2) and the isotype control mAb
(F632) were administered by an intravenous injection into
the animals’ penile vein, at an individual dose of 50 μg
dissolved in 200 μl sterile PBS. Injections were per-
formed immediately prior to the experimental condition
(head injury or sham surgery), and repeated at t =
24 hours for analysis of samples at later time-points be-
yond 24 hours. The reconstitution of pathogenic natural
antibodies occurred after the neurological scoring
(NSS) at 24 hours. The selected dosage was determined
by previous dose-response studies in Rag1-/- mice,
showing no difference in the extent of pathogenic ef-
fects at doses between 25 μg and 100 μg per mouse
[23,24].
Statistical analysis
Statistical analysis was performed using commercially
available software (SigmaPlot 11.0, Systat Software, San
Jose, California, United States). The repeated measures
analysis of variance (ANOVA) was used to assess differ-
ences in NSS scores. Differences in post-injury mortality
were evaluated on a contingency table using χ2 and Fish-
er’s exact test as appropriate. Differences in serum and
plasma mediator levels determined by ELISA, as well as
between cohorts assessed by semi-quantitative counts
for TUNEL, GFAP, CD11b, and IgM, were evaluated by




Head-injured Cr2-/- mice showed a significantly improved
neurological outcome, as determined by a decreased NSS
from 1 hour to 72 hours after trauma (P <0.05), compared
to head-injured wild-type animals (Figure 2A). The NSS at
seven days was in a similar range between head-injured
Cr2-/- mice (2.29 ± 0.29), and wild-type animals (2.25 ±0.27), and in close proximity to the baseline NSS seen in
sham-operated mice in both groups, which reflects the
spontaneous neurological recovery at seven days after
trauma in this model [19]. Finally, the post-injury mor-
tality was significantly decreased in Cr2-/- mice (10%),
compared to wild-type mice (18%; P <0.05; Figure 2B).
Neuronal cell death
TUNEL histochemistry was performed in coronal brain
sections of Cr2-/- and wild-type mice to assess the extent
of intracerebral cell death after closed head injury. Very
low baseline TUNEL fluorescence signals (red) were
detected in the cortex of sham-operated mice in both
groups (Figure 3). The mean cell count of TUNEL-
positive cells increased dramatically in the injured
cortex of wild-type mice at seven days post injury, com-
pared to head-injured Cr2-/- mice and sham-operated
animals (P <0.05). Double-staining with anti-NeuN as a
neuronal cell marker (in green fluorescence) revealed
that neurons were the predominant TUNEL-positive
cell type (Figure 3).
Complement C3 release in injured brains
Homogenized brain tissue and plasma samples were ana-
lyzed by western blotting for protein levels of the comple-
ment component C3. In analogy with findings from
previous studies [8,10], C3 was upregulated in the brains
of head-injured wild-type mice, compared to sham-
operated controls, as shown in a representative western
blot (Figure 4A). In contrast, brain homogenates from
Cr2-/- mice displayed a marked reduction of C3 protein
levels after TBI, as quantified by densitometric analysis
of the same representative blot shown in Figure 4A.
Attenuated C3 levels in Cr2-/- mice were specific to the
injured left hemisphere, whereas the uninjured right
(control) hemisphere showed similar C3 levels between
the groups. In contrast to attenuated C3 levels in brain
tissue from Cr2-/- mice, western blot analysis of plasma
samples revealed no difference in C3 levels between
head-injured Cr2-/- and wild-type mice, which implies
that CR2/CR1-mediated effects related to binding of C3
fragments released after head injury are specific to the
intracranial compartment. These findings are supported
by IHC experiments which revealed an attenuated ex-
tent of C3 tissue deposition in injured brains of Cr2-/-
mice compared to wild-type animals (Figure 4B).
Activation of astrocytes and microglia
Cellular activation patterns of astrocytes and microglia
were examined by IHC staining of serial coronal brain
sections, using specific cell markers as primary anti-
bodies (Figure 5). At 24 hours after TBI, brains from
wild-type mice showed massive increase in staining in-
tensity for GFAP-positive astrocytes (Figure 5A) and for
Figure 2 Improved neurological outcomes and decreased post-injury mortality of Cr2-/- mice after traumatic brain injury (TBI). Cr2-/- mice
showed a significantly decreased Neurological Severity Score (NSS) from 1 hour to 72 hours after brain injury (A), and a significantly decreased
seven-day mortality (B), compared to wild-type littermates. *P 0.05, repeated measures ANOVA (NSS); and χ2 test (mortality). Sham-operated
animals served as internal controls. Data are shown as mean values ± SD.
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white matter of injured hemispheres. Cell counts of acti-
vated glial cells revealed that the intensity of cellular
signals was significantly increased in head-injured wild-
type animals compared to Cr2-/- mice and sham controls
(P <0.05; Figure 5C).Figure 3 Neuronal cell death is reduced in the injured brain
hemispheres of Cr2-/- mice at seven days after traumatic brain
injury (TBI). Coronal cryosections of injured left hemispheres of
wild-type and Cr2-/- mice at seven days after sham operation or
closed head injury were double-stained with a monoclonal anti-NeuN
in green fluorescence (FITC) and by TUNEL technique in red
fluorescence (TRITC), followed by visualization of cellular signals
by fluorescence microscopy. Semi-quantitative analysis of cell-counts
revealed a significantly increased number of TUNEL-positive neurons in
the injured cortex of wild-type animals, compared to head-injured
Cr2-/- mice and sham-operated controls. The TUNEL-positive cells
were counted in 15 randomly selected cortical fields of 0.01 mm2
per section. Cell counts are shown as mean values ± SD. *P <0.05
for wild-type TBI compared to Cr2-/- TBI and sham controls. IHC,
immunohistochemistry; TBI, traumatic brain injury.Mediators of cell death and inflammation
To investigate the potential mechanisms of attenuated
neuronal cell death in head-injured Cr2-/- mice, protein
levels of selected apoptotic mediators in brain homoge-
nates were assessed by western blot analysis. No differ-
ences in Fas, Fas-L, Bax, and Bcl-2 protein levels were
observed at any time-point between head-injured Cr2-/-
compared to wild-type mice (Figure 6). These data imply
that selected mediators of the extrinsic (Fas and Fas-L)
and intrinsic (mitochondrial) pathway of apoptosis (Bax
and Bcl-2) are not involved in the CR2/CR1-dependent
regulation of neuronal cell death in our model of closed
head injury in mice.
For further investigation of potential underlying mech-
anisms of neuroprotection observed in head-injured
Cr2-/- mice, we investigated serum levels of NSE, as a
surrogate marker of neuronal injury, selected pro- and
anti-inflammatory cytokines (TNF, IL-6, and IL-10), and
the plasma levels of the C3-derived anaphylatoxin C3a,
by ELISA at t = 4 hours, 24 hours, and 7 days after
trauma or sham surgery. Closed head injury induced a
significant increase of serum IL-6 and NSE levels, as well
as C3a plasma levels at 24 hours, in wild-type mice com-
pared to sham-operated littermates (P <0.05; Figure 7).
However, no significant differences in mediator levels
were observed between head-injured Cr2-/- and wild-
type mice, at any time-point after trauma.
Role of natural IgM
In light of the known protection of Cr2-/- mice to tissue
injury related to the lack of CR2-dependent signal trans-
duction through the B cell receptor on B1 cells, one
of the mechanisms of neuroprotection seen in head-
injured Cr2-/- mice may relate to the attenuated release
of pathogenic natural IgM antibodies which target neo-
epitopes on injured cells [15]. In order to determine
Figure 4 Attenuated intracerebral complement C3 levels in head-injured Cr2-/- mice at 24 hours post injury. Panel A shows a
representative western blot of brain homogenates from injured (left) and uninjured (right) hemispheres of wild-type and Cr2-/- mice at 24 hours
after head injury or sham surgery, using a monoclonal anti-mouse C3 antibody. Equal protein loading (50 μg per lane) was ensured by control
blotting with β-actin. Closed head injury induced an increase of C3 protein levels in the injured hemispheres of wild-type mice compared to sham
controls. In contrast, head-injured Cr2-/- mice showed attenuated intracerebral C3 levels in the injured left hemisphere. Pixel intensity for densitometric
quantification was determined using ImageJ software. The western blot shown in the figure is representative of four individual experiments. Panel B
demonstrates the extent of C3 brain tissue deposition by immunohistochemistry using monoclonal anti-mouse C3 as primary antibody. Similarly as
shown by the western blot data, C3 tissue deposition was attenuated in head-injured Cr2-/- mice, compared to wild-type littermates. The inserts in the
upper panel (40 ×) reflect the according selection in the corresponding higher magnification images (100 ×). TBI, traumatic brain injury.
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through direct mechanisms related to the absence of
CR2 and CR1, or indirectly by dysfunction of the CR2-
dependent natural IgM repertoire, we performed add-
itional IHC experiments to stain for IgM deposition in
injured brains. Using antibodies specific for the im-
munoglobulin μ chain, low background staining was
seen in sham-operated wild-type and Cr2-/- mice sacri-
ficed at 24 hours (Figure 8A). Head-injured wild-type
mice showed a significant increase in IgM deposition at
24 hours after trauma by semi-quantitative signal count
analysis (P <0.05; Figure 8B). In contrast, Cr2-/- mice
had a drastically attenuated IgM staining pattern in in-
jured brains, which was similar to the baseline stainingseen in sham-operated mice (Figure 8). These data sug-
gest that indirect mechanisms related to a defective IgM
repertoire in the absence of CR2 on B1 cells may be in
part responsible for the neuroprotective features seen in
head-injured Cr2-/- mice.
In order to further elaborate on the potential role of
pathogenic natural IgM in contributing to secondary
brain damage after TBI, additional experiments were
designed in Rag1-/- mice which lack B cells and T cells,
and therefore lack a natural antibody repertoire [20].
For this purpose, reconstitution experiments were per-
formed with selected pathogenic natural antibodies
against annexin IV (mAb B4) or phospholipids (mAb C2)
which had been previously linked to the pathogenesis of
Figure 5 Glial reaction is attenuated in Cr2-/- mice at 24 hours after traumatic brain injury (TBI). Immunohistochemistry of coronal brain
cryosections was performed using glial fibrillary acidic protein (GFAP) as a specific marker for astrocytes (A) and CD11b as a cellular marker for
microglia (B). The inserts in the upper panel (40 ×) reflect the according selection in the corresponding higher magnification images (200 ×). Cell
counts of immunostained sections revealed that signals for GFAP and CD11b were significantly increased in the injured left hemispheres of wild-type
mice, compared to head-injured Cr2-/- littermates (C). Activated glial cells were counted in 10 randomly selected cortical fields of 0.01 mm2 per section
and per cell marker. Cell counts were performed using QCapturePro7 software (QImaging).and values are shown as mean values ± SD. *P <0.05 for
wild-type TBI compared to Cr2-/- TBI and sham controls.
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including ischemic stroke and intestinal ischemia/re-
perfusion injury [23,24]. Head-injured Rag1-/- mice
reconstituted with pathogenic natural IgM showed no
difference in neurological outcomes (NSS) for up to
seven days, compared to Rag1-/- mice without reconsti-
tution or with injection of non-pathogenic IgM (mAb
F632), as negative control (Figure 9).Discussion
The present study was designed to evaluate the role of
CR2 and CR1, which are mainly expressed by B lympho-
cytes, in contributing to the secondary neuropathological
sequelae of TBI. As these receptors have been implicated
in the immunopathology of tissue injury in a variety of
inflammatory conditions in and outside of the CNS, we
hypothesized that mice with an inactive Cr2 gene would
Figure 6 Selected pro- (Fas, FasL, and Bax) and anti-apoptotic
(Bcl-2) mediator levels in brain homogenates. Samples were
analyzed by western blots of injured (left) and non-injured (right)
hemispheres at seven days after traumatic brain injury (TBI) or sham
operation. Equal concentrations of protein (50 μg per lane) were
loaded on SDS-Page, and consistent loading was confirmed by β-Actin
control blotting. Mouse-specific primary antibodies against Fas, FasL,
Bax, and Bcl-2 were used on nitrocellulose membranes and visualized
by a colorimetric assay using alkaline-phosphatase. No differences
in mediator levels were detected between the groups at any
time-point assessed.
Figure 7 Peripheral levels of selected biomarkers and
inflammatory mediators in wild-type (WT) and Cr2-/- mice at
24 hours after closed head injury or sham surgery. Serum and
plasma samples were analyzed by mouse-specific ELISA. Final mediator
concentrations were normalized by total protein content of the
samples, as described in the Materials and methods section.
Head-injured mice showed a significant increase in mediator levels at
24 hours, compared to sham-injured animals (*P <0.05). However, there
was no difference in concentrations between head-injured WT and
Cr2-/- mice. Data are shown as mean values ± SD and are representative
of n = 22 WT and n = 13 Cr2-/- mice.
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model of experimental closed head injury [19]. Indeed,
head-injured Cr2-/- mice displayed a significantly im-
proved neurological outcome, significantly reduced post-
traumatic mortality, attenuated extent of neuronal cell
death and of post-injury astrogliosis, and reduced intra-
cerebral complement C3 deposition compared to wild-
type littermates. Complement C3 accumulation in the
injured cortex has been previously described in a fluid-
percussion TBI model in mice, and intracerebral C3d
deposition was found in post-ischemic mouse brains fol-
lowing experimental ischemic stroke [8,24]. In addition,
the CNS-targeted blockade of C3 convertases in GFAP-
Crry transgenic mice resulted in significantly improved
neurological outcomes for up to four weeks after closed
head injury, based on the identical experimental model
used in the present study [11]. Insights from pharmaco-
logical approaches of inhibiting C3 convertases in experi-
mental TBI models support the notion of complement
C3-derived downstream activation products playing a cru-
cial contributory role in post-injury neuroinflammation
and neurodegeneration [13,25]. In these studies, neuronal
subsets in the hippocampal layers with the highest vulner-
ability to closed-head injury were protected by pharmaco-
logical inhibition of C3 convertases [13]. A more recent
study confirmed this finding by demonstrating that the C3
Figure 8 IgM deposition is attenuated in Cr2-/- mice at 24 hours after traumatic brain injury (TBI). Immunohistochemistry of coronal brain
cryosections was performed using an antibody specific to the μ chain for detection of IgM. Tissue deposition of IgM was markedly increased in
the injured left hemispheres of wild-type mice. In contrast, head-injured Cr2-/- mice showed low basal levels of IgM signals, to a similar extent as
in sham-operated control mice (A). The inserts in the upper panel (40 ×) reflect the according selection in the corresponding higher magnification
images (200 ×). For quantitative analysis, IgM signals were counted in 20 randomly selected cortical fields of 0.01 mm2 per section (B). Cell counts were
performed using QCapturePro7 software (QImaging).and values are shown as mean values ± SD. *P <0.05 for wild-type TBI compared to Cr2-/- TBI and
sham controls. IgM, immunoglobulin M.
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neurogenesis, and that this pathogenic effect is mitigated
in Cr2-/- mice [26]. Arguably, this striking finding provides
a potential explanation for the improved neurological out-
comes in head-injured Cr2-/- mice seen in the present
study (Figure 2). This notion is supported by the observa-
tion of decreased C3 deposition in injured brains from
Cr2-/- mice by IHC, and decreased C3 protein levels in
brain homogenates by western blotting (Figure 4), imply-
ing a causative role of C3-derived complement activation
fragment binding to CR2 and/or CR1 on these cells.
In addition to the proposed protective mechanism related
to the lack of CR2 ligand binding (C3d, C3dg, and iC3b) in
head-injured Cr2-/- mice, the absence of CR2 and CR1 also
appeared to protect from neuronal cell death in cortical
neurons in injured brain hemispheres (Figure 3). We have
previously shown that secondary neuronal cell death may
be in part mediated by the terminal complement pathway
through the membrane attack complex (MAC), and that
the membrane-bound complement regulator CD59 pro-
tects from secondary cerebral insults and delayed neuronal
cell death [22,27]. As one of the apparent mechanisms
may be represented by programmed cell death throughdistinct apoptotic pathways, we sought to investigate the
protein levels of selected apoptotic mediators of the ex-
trinsic and intrinsic (mitochondrial) pathway of apoptosis
in brain homogenates from Cr2-/- and wild-type mice.
Strikingly, no difference in protein levels of any of the se-
lected pro- (Fas, FasL, and Bax) and anti-apoptotic (Bcl-2)
mediators investigated in this study was seen between
head-injured Cr2-/- and wild-type mice, at any time-point
investigated (Figure 6). These findings support the notion
that mechanisms of protection from secondary neuronal
cell death in the Cr2-/- genotype are independent of apop-
totic mechanisms and programmed cell death.
A different perspective of secondary host-mediated
neuropathology relates to the crucial role of CR2 in the
development and regulation of pathogenic natural anti-
bodies targeting neo-epitopes expressed in injured tissue
[15]. The Cr2-/- phenotype is characterized by multiple
immunological alterations, including an altered natural
antibody repertoire and impaired B cell responses to
antigen exposure [15,18]. In the present study we found
a decreased extent of IgM deposition in the injured
brains of Cr2-/- mice compared to head-injured wild-
type littermates (Figure 8). This finding is suggestive of a
Figure 9 Reconstitution of selected pathogenic natural
antibodies in immunodeficient Rag1-/- mice. The pre-injury
reconstitution of mAbs against annexin IV (mAb B4) and phospholipids
(mAb C2) did not alter the neurological outcome in head-injured
Rag1-/- mice which lack a natural antibody repertoire. The Neurological
Severity Score (NSS) was assessed for up to seven days after closed
head injury in Rag1-/-mice. No significant difference was seen in
neurological outcomes between head-injured Rag1-/- mice with or
without reconstitution of pathogenic natural antibodies (mAb B4 and
mAb C2) or mAb F632 as an isotype-matched control antibody
(repeated measures ANOVA; P >0.05). IgM, immunoglobulin M.
Figure 10 Presumed mechanisms of CR2-mediated secondary
neuropathology after closed head injury. See discussion for
detailed explanations. BCR, B cell receptor; CR2, complement receptor
type 2.
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nal transduction and IgM release by B cells, in contrib-
uting to host-mediated secondary neuropathology after
closed head injury. Natural antibodies are ‘hard-wired’
components of the immune system that circulate in ab-
sence of specific antigen exposure or immunization and
exhibit several different types of functional attributes
[15]. Some natural antibodies are low-affinity, polyreac-
tive, non-immunized antibodies of the IgM isotype
which are produced by a subset of B cells (termed B-1
cells) and represent a bridge between innate and adap-
tive immune responses [15,28]. Other natural antibodies
have been shown to contribute to immunological
homeostasis under physiological conditions and to the
development of autoimmune disease [29]. In experimen-
tal studies, an additional subset of non-polyreactive
pathogenic natural antibodies has been shown to medi-
ate tissue damage in various models of ischemia/reperfu-
sion injury and ischemic cerebrovascular stroke in mice
[16,23,24]. The presumed mechanism manifested by these
antibodies is the recognition of neo-antigens present on
the surface of ischemic tissues, with subsequent patho-
genic complement activation during the reperfusion
phase, leading to unintentional host cell death [29-31]. In
light of the impaired signal transduction in the absence of
CR2 on B1 cells, and subsequently altered natural anti-
body response in Cr2-/- mice, we designed an additional
set of experiments aimed at elucidating the potential roleof selected pathogenic natural IgM in contributing to sec-
ondary neuropathology in our model of closed head in-
jury. For this purpose we used mice deficient in the Rag1
gene (Rag1-/-) which are genetically devoid of mature B
and T lymphocytes and therefore lack the complete nat-
ural antibody repertoire [20]. In contrast, the absence of
CR2 expression by B lymphocytes in Cr2-/- mice leads to
an altered natural antibody repertoire, but these mice are
still capable of producing natural IgM [15]. Rag1-/- mice
were reconstituted with two selected natural IgM against
annexin IV and phospholipids, which have previously been
shown to exert pathogenic effects in other mouse models
of inflammation-mediated tissue injury (mAb B4 and
mAb C2) [23,24,32]. Strikingly, we found that the pre-
injury reconstitution of either mAb B4 or mAb C2 in im-
munocompromised Rag1-/- mice does not alter the neuro-
logical outcome in comparison to head-injured Rag1-/-
mice injected with a non-pathogenic control IgM (mAb
F632), or to Rag1-/- mice without IgM reconstitution
(Figure 9). In addition, the extent of complement activa-
tion at the C3 level and of complement C3 deposition in
injured brain tissue was not altered in head-injured Rag1-/-
mice with or without IgM reconstitution (data not shown).
Finally, neither the extent of post-injury neuronal cell
death, nor the levels of selected mediators of cell death and
inflammation were altered by reconstitution of natural
antibodies in Rag1-/- mice (data nor shown). These findings
suggest that the two selected natural IgM investigated in
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properties which contribute to the evolution of secondary
brain injury in this model of closed head injury in mice.
The exact cellular and molecular mechanisms of CR2-
mediated neuropathology seen in the present study remain
speculative. Conceivably, the homeostasis between protect-
ive and harmful natural antibodies may be of crucial im-
portance and outweigh the isolated pathogenic effects of
the two selected natural IgM investigated in this study [33].
Similarly, the underlying root cause of the impressive
attenuation of the extent of post-injury glial activation
observed in head-injured Cr2-/- mice in this study (Figure 5)
remains a topic of speculation. Recent studies have empha-
sized an important role for activated microglia and reactive
astrocytosis in contributing to post-injury neuroinflamma-
tion and adverse outcomes [34-36]. A recently published
experimental study using the controlled cortical impact
(CCI) model in Wistar rats revealed that microglial activa-
tion after focal TBI peaked within the first three to seven
days post injury which reflects a similar timeline of cellular
activation observed in the present study [34].
Impressively, a landmark article by Gasque et al. reported
the expression of complement C3 receptors (CR1, CR2,
and CR3) by human astrocytes in vitro [37]. The CR2
expressed on astrocytes was shown to be functional, as
demonstrated by Epstein-Barr virus infection through the
CR2 expressed in human astrocyte cell lines [38]. In a
different study on a rat model of TBI, Bellander et al. were
able to correlate enhanced microglial activation with intra-
cerebral complement C3 expression at seven days post in-
jury [9], which reflects the same time-window analyzed in
our current study. Taken together, these data support the
notion that complement C3 contributes to increased astro-
cytosis and microglial activation after TBI, likely through
the CR2 expressed on astrocytes, and through indirect
mechanisms on microglia since the latter cell-type does not
express CR2 [9,37]. Our current findings of attenuated
post-injury glial reaction in absence of the Cr2 gene support
this hypothesis (Figure 5). However, a potential role of CR1
in contributing to the post-injury neuropathology observed
in our TBI model cannot be excluded, as the mouse Cr2
gene encodes both CR2 and CR1 receptors by alternative
splicing and Cr2-/- mice are therefore deficient in both CR2
and CR1 [17,18].
Our current understanding of the potential underlying
mechanisms of CR2-mediated neuropathology after TBI is
depicted in a schematic diagram shown in Figure 10. In
light of the recent availability of a new generation of recom-
binant chimeric compounds which link CR2 to inhibitors
of the complement system, future studies should be
designed to investigate the potential benefit of pharma-
cological modulation of CR2-mediated functions and of
CR2-linked targeting of C3-derived complement frag-
ments at the site of tissue injury [39].Abbreviations
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